The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
Concentration:
0.2 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Application:
ICFC - Quality tested
Recommended Usage:
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤ 0.1 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
FACS sorted naive CD4 T cells (CD44lo, CD25-) were cultured on plates coated with 1 µg/ml anti-CD3 and 10 µg/ml anti-CD28 in the presence of 10 ng/ml IL-4 and 5 ng/ml TGFβ for 3 days. Intracellular staining was performed following a 4h restimulation with PdBU/ionomycin/brefeldin. Data kindly provided by: Dr. Brigitta Stockinger, PhD
Description:
IL-9 is a potent, T cell-derived, T cell growth factor which can also enhance mast cell activity and IL-3- or IL-4- dependent proliferation of bone marrow-derived mast cells. IL-9 synergizes with erythropoietin to promote erythroid colony formation. IL-9 induces high affinity IgE receptor expression and granzyme A and B in murine T helper clones. The RM9A4 antibody reacts with mouse IL-9.
Upregulated by IL-1 after TCR activation, TNF-α; downregulated by antibodies to IL-2
Cellular Sources:
IL-2 activated TH2 lymphocytes
Cellular Targets:
T lymphocytes, erythroid precursors
Receptors:
IL-9R
Bioactivity/Activities:
Potentiates production of IgG, IgM, and IgE by IL-4-induced B lymphocytes; regulates granzyme family proteases; enhances proliferation of bone marrow mast cells with IL-3; production of IL-6 by mast cells
Antigen References:
1. Fitzgerald, K., et al., Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. Quesniaux, V., et al., 1992. Research Immunology 143:385. 3. Renauld, J., et al., 1993. Adv. Immunol. 54:79. 4. Yang, Y., et al., 1992. Leuk. Lymphoma 8:441.
